Apira Science, Inc. today announced that it has received clearance to sell and distribute the iGrow Hair Growth System in South Korea, Thailand, Singapore, and Egypt. These latest clearances underscore Apira’s growing global reach, which stretches across five continents.
Clearances from the Korea Food and Drug Administration (KFDA), FDA Thailand, the Singapore Health Sciences Authority (HSA), and the Egyptian Ministry of Health (MoHP) bring iGrow’s patented low-level light therapy (LLLT) technology to these markets. These four countries add to the territories where iGrow is already approved, including the United States, all 28 European Union nations, Canada, Mexico, Hong Kong, India, Peru, and Turkey.
The iGrow Hair Growth System is an innovative, safe, and effective hands-free LLLT hair growth device cleared by the FDA for at-home use. In clinical studies, the iGrow’s patented red light technology, which consists of a highly productive combination of red laser and LED diodes, increased hair growth 37 percent after 16 weeks of therapy, and nearly doubled total hair growth 10 weeks faster than hand-held laser combs and brushes.
“Hair thinning and baldness extends across borders and continents with no regard for nationality, age, or gender,” said Jeff Braile, president of the Medical Products Division at Apira. “Adding certification in four new Asian and Middle Eastern countries brings a clinically proven LLLT treatment to those suffering from androgenetic alopecia and other causes of hair loss. And we are continuing our expansion, with clearances expected in a number of additional major markets prior to year-end.”
For more information on the iGrow Hair Growth System, visit www.igrowlaser.com.
About Apira Science, Inc.
Apira Science, Inc. has pioneered low-level light therapy (LLLT) for over a decade. Its iGrow Hair Growth Platform draws on its expertise and innovations in the application of LLLT to deliver a simple, safe, and effective hair growth treatment.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151115005023/en/